
This Update consists of four modules covering new and changing knowledge on:


This Update consists of four modules covering new and changing knowledge on:

|
|
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of drugs initially developed to treat type 2 diabetes and are now becoming more widely used for obesity. They work by mimicking the actions of the GLP-1 hormone, which is released by the gut after eating. GPs will be used to prescribing them for type 2 diabetes, but less so for obesity. In this podcast, Dr Thomas Round discusses the evolving role of GLP1-RA in obesity, the benefits and potential side effects, the role of the GP, and the latest NICE guidance in this area with Dr Stephanie DiGiorgio, an urgent care GP with a specialist interest in obesity. This podcast falls within the Metabolic Problems and Endocrinology curriculum field. Production, editorial, and distribution owned by the Royal College of General Practitioners.
|

|
|
This course provides a variety of resources (grouped by topic and format e.g. eLearning, guidelines, courses and books) on the subject of gynaecology and breast. Topics include:
|

Available until 18 December 2026.
The prevalence of ketamine use has increased markedly over the past few years, with the number of people seeking treatment for ketamine use disorder increasing 12-fold over the past decade. Patients often have additional medical problems relating to those outside of the addiction itself and at times can present with a complex array of symptoms.
This webinar will give an overview of ketamine use disorder and the associated ketamine uropathy to enable you to identify and manage patients with the disorder presenting in your practice. It is hoped that the session will not only improve your knowledge on the subject but encourage a more joined up approach between medical services, to ultimately improve patient outcomes and reduce adverse events in this vulnerable and young cohort of patients.
Learning objectives:

